About
TheraMe! AG is a MedTech startup based in Lausanne, Switzerland, focused on personalized cancer therapy using advanced microfluidic technology. Founded in 2023 as a spin-off from EPFL, the company develops innovative diagnostic solutions that test drug responses directly on live tumor cells from patient biopsies. Their proprietary microfluidic platform allows for functional drug screening with minimal tumor material, enabling rapid and precise therapy recommendations. The company is working on an automated in vitro diagnostic (IVD) instrument in collaboration with the Swiss Center for Electronics and Microtechnology (CSEM). This device aims to streamline the drug screening process, enhancing clinical applicability for personalized treatment decisions. TheraMe! has a multidisciplinary team with expertise in various fields, which supports its innovative capacity. The company has received multiple grants and awards, recognizing its potential in the healthcare sector. TheraMe!'s primary customers include healthcare providers and clinical laboratories looking for personalized cancer treatment solutions. Their technology integrates into clinical workflows, assisting oncologists in selecting the most effective therapeutic options for individual patients.
Technologies
Keywords
Company Information
-
Employees 7
-
Founded 2023
Location
5 Route de la Corniche, Epalinges, Vaud, Switzerland, 1066
